Lockstat 10 Tablet

Rosuvastatin acts by inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby decreasing cholesterol production in the liver and promoting the clearance of LDL particles from the bloodstream. Lockstat 10 is prescribed for patients with primary hyperlipidemia, familial hypercholesterolemia, and for the prevention of cardiovascular disease in individuals at high risk due to factors such as diabetes, hypertension, or a history of coronary artery disease.

The recommended dosage is typically one tablet daily, with or without food, and should be individualized based on patient response and lipid profile. Regular monitoring of liver function tests and lipid levels is advised during therapy. Caution is warranted in patients with hepatic impairment, renal dysfunction, or a history of muscle disorders. Lockstat 10 should be used as part of a comprehensive treatment plan including diet, exercise, and lifestyle modifications to achieve optimal cardiovascular risk reduction.